3 nominees · 3 ballot items.
Elect three Class II directors; Ratify Ernst & Young LLP as independent auditors; Advisory approval of Named Executive Officers’ compensation (say-on-pay).
Elect three Class II director nominees (Rodney D. Windley, Sam Weil, Steven E. Rodgers) to serve three-year terms expiring at the 2029 Annual Meeting.
Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accountants for the fiscal year ending January 2, 2027.
Approve, on an advisory, non-binding basis, the compensation paid to the Company’s Named Executive Officers as disclosed in the Proxy Statement.
The advisory, non-binding proposal asks shareholders to approve the compensation of the Company’s Named Executive Officers as disclosed in the proxy materials. Management seeks this advisory approval to satisfy SEC and Dodd-Frank requirements and to solicit shareholder feedback on executive pay. The Compensation Committee designs pay to be performance-based and aligned with stockholder interests, using a mix of base salary, annual cash incentives tied to revenue and Adjusted EBITDA, and long-term incentives (50% RSUs, 50% PSUs tied to Adjusted EBITDA). The Compensation Committee retained an independent consultant, Aon, and uses peer group benchmarking and discretion in setting levels, with target bonuses and multi-year vesting to align incentives. The Board recommends a “FOR” vote, citing alignment of compensation with performance, substantial payouts tied to 2025 results (many NEOs received 200% of target annual bonuses), and governance safeguards like equity vesting, ownership guidelines, and a cap at 200% for annual incentives. Management notes the vote is non-binding but will be considered in future decisions. The proposal is routine in format but touches on material governance issues, given significant payouts in 2025 and the Company’s controlled-company status which may affect governance oversight. Shareholders should weigh the strong pay-for-performance evidence from 2025 against potential governance concerns and the structure of long-term incentives when evaluating the proposal.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAIN CAPITAL INVESTORS LLC | 37.5% | 81,600,880 | $526M |
| 2 | J.H. Whitney Equity Partners VII, LLC | 16.6% | 36,242,631 | $233M |
| 3 | Nut Tree Capital Management, LP | 5.9% | 12,922,649 | $83M |
| 4 | SUMMIT PARTNERS L P | 2.5% | 5,451,422 | $35M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1.8% | 3,974,819 | $26M |
| 6 | Boston Partners | 1.2% | 2,712,897 | $17M |
| 7 | BlackRock, Inc. | 1.0% | 2,236,293 | $14M |
| 8 | BRAIDWELL LP | 1.0% | 2,203,506 | $14M |
| 9 | LITTLEJOHN CO LLC | 1.0% | 2,203,362 | $14M |
| 10 | BlackRock, Inc. | 0.9% | 2,041,599 | $13M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.